Concepedia

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Stephen A. Harrison, Federico Pérez Manghi, William B. Smith, Diana Alpenidze, Diego Aizenberg, Naomi B. Klarenbeek, Chi-Yi Chen, Eli Zuckerman, Éric Ravussin, Phunchai Charatcharoenwitthaya,

Nature Medicine · 2022 · 72 citations · 22 references

DOIFull text

Open access

Concepts

References

22

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Journal of Hepatology · 2016 · 4.8K citations

, , +9

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

Eduardo Vilar‐Gómez, Yadina Martínez-Pérez, Luis Calzadilla Bertot et al. · Gastroenterology · 2015 · 2.4K citations · Full text

, , +11

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

, , +14

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

Christopher D. Williams, Joel Z. Stengel, Michael Asike et al. · Gastroenterology · 2010 · 2.2K citations · Full text

, , +14

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 765 citations

, , +9